Actionable molecular biomarkers in primary brain tumors
- PMID: 28603776
- PMCID: PMC5461965
- DOI: 10.1016/j.trecan.2016.06.003
Actionable molecular biomarkers in primary brain tumors
Abstract
Recent genome-wide studies of malignancies of the central nervous system (CNS) have revolutionized our understanding of the biology of these tumors. This newly gained knowledge provides a wealth of opportunity for biomarker driven clinical research. To date, however, only few of the available molecular markers truly influence clinical decision-making and treatment. The most widely validated markers in neuro-oncology presently are: 1) MGMT promoter methylation as a prognostic and predictive marker in glioblastoma, 2) co-deletion of 1p and 19q differentiating oligodendrogliomas from astrocytomas, 3) IDH1/2 mutations, and 4) select pathway-associated mutations. This article focuses on currently impactful biomarkers in adult and pediatric brain cancers and it provides a perspective on the direction of research in this field.
Keywords: BRAF mutation; Biomarker; IDH mutation; MGMT promoter methylation; co-deletion of 1p/19q; glioblastoma; glioma; medulloblastoma.
References
-
- Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta neuropathologica. 2016;131(6):803–20. doi: 10.1007/s00401-016-1545-1. - PubMed
-
- Holdhoff M, Ye X, Blakeley JO, et al. Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. J Neurooncol. 110(2):279–85. doi: 10.1007/s11060-012-0968-3. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous